Mechanisms of cardiorenal protection with SGLT-2 inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Current pharmaceutical design"
DOI: 10.2174/1381612827666210119102409
Abstract: Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially high. There is therefore an unmet need… read more here.
Keywords: cardiovascular outcomes; sglt inhibitors; sglt; cardiorenal protection ... See more keywords
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Biomolecules"
DOI: 10.3390/biom12101349
Abstract: Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are novel drugs… read more here.
Keywords: biomolecular mechanisms; mechanisms cardiorenal; cardiorenal protection; protection sodium ... See more keywords
Cardiorenal Protection in Diabetic Kidney Disease
Sign Up to like & getrecommendations! Published in 2021 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2021.987
Abstract: Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control,… read more here.
Keywords: cardiorenal protection; diabetic kidney; disease; kidney ... See more keywords